- Home
- Publications
- Publication Search
- Publication Details
Title
Tumour burden and efficacy of immune-checkpoint inhibitors
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 19, Issue 2, Pages 75-90
Publisher
Springer Science and Business Media LLC
Online
2021-10-12
DOI
10.1038/s41571-021-00564-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Mitochondrial stress induced by continuous stimulation under hypoxia rapidly drives T cell exhaustion
- (2021) Nicole E. Scharping et al. NATURE IMMUNOLOGY
- Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆
- (2021) D.R. Spigel et al. ANNALS OF ONCOLOGY
- Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia
- (2021) Andrew H. Wei et al. LEUKEMIA
- Metabolic support of tumour-infiltrating regulatory T cells by lactic acid
- (2021) McLane J. Watson et al. NATURE
- Harnessing Tumor Necrosis Factor Alpha to Achieve Effective Cancer Immunotherapy
- (2021) María Florencia Mercogliano et al. Cancers
- PD-L1 Expression in Circulating Tumor Cells as a Promising Prognostic Biomarker in Advanced Non–small-cell Lung Cancer Treated with Immune Checkpoint Inhibitors
- (2021) Filippo G. Dall'Olio et al. Clinical Lung Cancer
- Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition
- (2021) Sarah Knispel et al. EUROPEAN JOURNAL OF CANCER
- Baseline total metabolic tumour volume on 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography-computed tomography as a promising biomarker in patients with advanced non–small cell lung cancer treated with first-line pembrolizumab
- (2021) Filippo G. Dall’Olio et al. EUROPEAN JOURNAL OF CANCER
- Pre-treatment tumor size impacts on response to nivolumab in head and neck squamous cell carcinoma
- (2020) Hiroto Inoue et al. AURIS NASUS LARYNX
- Combination of Immunotherapy and Radiotherapy—The Next Magic Step in the Management of Lung Cancer?
- (2020) Lizza E.L. Hendriks et al. Journal of Thoracic Oncology
- Immunotherapeutic approaches for small-cell lung cancer
- (2020) Wade T. Iams et al. Nature Reviews Clinical Oncology
- Lactate dehydrogenase: a marker of diminished antitumor immunity
- (2020) Sandra Van Wilpe et al. OncoImmunology
- Longitudinal monitoring of ctDNA in patients with melanoma and brain metastases treated with immune checkpoint inhibitors
- (2020) Jenny H Lee et al. CLINICAL CANCER RESEARCH
- Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4
- (2020) Romain-David Seban et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer
- (2020) Taiki Hakozaki et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors
- (2020) Kurt A. Schalper et al. NATURE MEDICINE
- Lack of Association Between Radiographic Tumor Burden and Efficacy of Immune Checkpoint Inhibitors in Advanced Lung Cancer
- (2020) Vinita Popat et al. ONCOLOGIST
- 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma
- (2020) Annie Wong et al. CANCER IMAGING
- Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer
- (2020) Kosuke Hashimoto et al. Journal of Clinical Medicine
- The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No
- (2020) V. Prasad et al. ANNALS OF ONCOLOGY
- The association between active tumor volume, total lesion glycolysis and levels of S-100B and LDH in stage IV melanoma patients
- (2020) E.A. Deckers et al. EJSO
- Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
- (2020) Andressa S Laino et al. Journal for ImmunoTherapy of Cancer
- Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study
- (2020) David Chardin et al. Journal for ImmunoTherapy of Cancer
- Optimization of the Enrichment of Circulating Tumor Cells for Downstream Phenotypic Analysis in Patients with Non-Small Cell Lung Cancer Treated with Anti-PD-1 Immunotherapy
- (2020) Maria A Papadaki et al. Cancers
- FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer
- (2020) Romain-David Seban et al. ANNALS OF NUCLEAR MEDICINE
- Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition
- (2020) Barzin Y. Nabet et al. CELL
- Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy
- (2020) Gabriela Marsavela et al. CLINICAL CANCER RESEARCH
- Circulating T-cell Immunosenescence in Patients with Advanced Non–small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy
- (2020) Roberto Ferrara et al. CLINICAL CANCER RESEARCH
- Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
- (2020) Aurélien Marabelle et al. LANCET ONCOLOGY
- Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i
- (2020) Reinhard Dummer et al. NATURE MEDICINE
- Clinical, FDG-PET and molecular markers of immune checkpoint inhibitor response in patients with metastatic Merkel cell carcinoma
- (2020) Alison M Weppler et al. Journal for ImmunoTherapy of Cancer
- Circulating Tumor DNA as a Prognostic Determinant in Small Cell Lung Cancer Patients Receiving Atezolizumab
- (2020) Guillaume Herbreteau et al. Journal of Clinical Medicine
- Correlating Radiomic Features of Heterogeneity on CT with Circulating Tumor DNA in Metastatic Melanoma
- (2020) Andrew B Gill et al. Cancers
- Characteristics of the Tumor Microenvironment That Influence Immune Cell Functions: Hypoxia, Oxidative Stress, Metabolic Alterations
- (2020) Ryan C. Augustin et al. Cancers
- Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis
- (2019) Zhibo Zhang et al. Cancer Medicine
- The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients
- (2019) M. G. Dal Bello et al. Journal of Translational Medicine
- Clinical Correlates of Response to Anti-PD-1–based Therapy in Patients With Metastatic Melanoma
- (2019) Elizabeth J. Davis et al. JOURNAL OF IMMUNOTHERAPY
- Baseline Tumor Size as a Predictive and Prognostic Factor of Immune Checkpoint Inhibitor Therapy for Non-small Cell Lung Cancer
- (2019) MASAHIRO KATSURADA et al. ANTICANCER RESEARCH
- Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer
- (2019) C G Kim et al. ANNALS OF ONCOLOGY
- Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials.
- (2019) Michael J. Sorich et al. Journal of Thoracic Oncology
- Tumor Mutation Burden—From Hopes to Doubts
- (2019) Alfredo Addeo et al. JAMA Oncology
- Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS
- (2019) Weina Zhang et al. CELL
- Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections
- (2019) Mary Philip et al. CURRENT OPINION IN IMMUNOLOGY
- Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics
- (2019) Romain-David Seban et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma
- (2019) Antoni Ribas et al. NATURE MEDICINE
- Immuno-Oncological Treatment and Tumor Mass in Non-Small Cell Lung Cancer: Case-Control Analysis of Overall Survival in Routine Clinical Practice
- (2019) Martin Faehling et al. ONCOLOGY
- Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors
- (2019) Menno Tamminga et al. Journal for ImmunoTherapy of Cancer
- Prognostic Relevance of Circulating Tumor Cells and Circulating Cell-Free DNA Association in Metastatic Non-Small Cell Lung Cancer Treated with Nivolumab
- (2019) Alama et al. Journal of Clinical Medicine
- Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
- (2019) Teofila Seremet et al. Journal of Translational Medicine
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
- (2019) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Site‐specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti–PD‐1 therapy
- (2019) Ines Pires da Silva et al. CANCER
- Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors
- (2019) Romain-David Seban et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Baseline tumor size and survival outcomes in lung cancer patients treated with immune checkpoint inhibitors
- (2019) Ashley M. Hopkins et al. SEMINARS IN ONCOLOGY
- A rationale for surgical debulking to improve anti-PD1 therapy outcome in non small cell lung cancer
- (2019) Florian Guisier et al. Scientific Reports
- Hyperprogressive Disease during Anti-PD-1 (PDCD1) / PD-L1 (CD274) Therapy: A Systematic Review and Meta-Analysis
- (2019) Jong Yeob Kim et al. Cancers
- Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
- (2019) Karen G. de la Cruz-López et al. Frontiers in Oncology
- Hyper-progressive Disease in Patients With Non–Small Cell Lung Cancer Treated With Checkpoint Inhibitors: The Role of 18F-FDG PET/CT
- (2019) Angelo Castello et al. JOURNAL OF NUCLEAR MEDICINE
- S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies
- (2018) Nikolaus B Wagner et al. BRITISH JOURNAL OF CANCER
- Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab
- (2018) Richard W. Joseph et al. CLINICAL CANCER RESEARCH
- Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients
- (2018) S. Valpione et al. EUROPEAN JOURNAL OF CANCER
- Metabolic Barriers to T Cell Function in Tumors
- (2018) Ayaka Sugiura et al. JOURNAL OF IMMUNOLOGY
- Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer
- (2018) L. Fehrenbacher et al. Journal of Thoracic Oncology
- PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
- (2018) Nicolas Guibert et al. LUNG CANCER
- Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma
- (2018) Arnaud Méjean et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Transmembrane TNF-alpha promotes chemoresistance in breast cancer cells
- (2018) Zunyue Zhang et al. ONCOGENE
- The hypoxic tumour microenvironment
- (2018) Varvara Petrova et al. Oncogenesis
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Laura Mezquita et al. JAMA Oncology
- The Predictive Value of Inflammation-Related Peripheral Blood Measurements in Cancer Staging and Prognosis
- (2018) Joanna L. Sylman et al. Frontiers in Oncology
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- The tumor suppressor menin prevents effector CD8 T-cell dysfunction by targeting mTORC1-dependent metabolic activation
- (2018) Junpei Suzuki et al. Nature Communications
- Hyperprogressive Disease in Patients With Advanced Non–Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
- (2018) Roberto Ferrara et al. JAMA Oncology
- Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy
- (2018) Kimiteru Ito et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- (2018) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Changes in hypoxia level of CT26 tumors during various stages of development and comparing different methods of hypoxia determination
- (2018) Łukasz Kiraga et al. PLoS One
- Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
- (2018) Axel Bex et al. JAMA Oncology
- Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors
- (2018) Fausto Petrelli et al. MELANOMA RESEARCH
- Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade
- (2018) Giuseppe Lo Russo et al. CLINICAL CANCER RESEARCH
- Very early response of circulating tumour–derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non–small cell lung cancer
- (2017) Yuki Iijima et al. EUROPEAN JOURNAL OF CANCER
- Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
- (2017) Frédéric Bigot et al. EUROPEAN JOURNAL OF CANCER
- Oxygen availability and metabolic reprogramming in cancer
- (2017) Hong Xie et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
- (2017) Michael J Overman et al. LANCET ONCOLOGY
- Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
- (2017) Christopher Abbosh et al. NATURE
- IL-6 and TNF-α promote metastasis of lung cancer by inducing epithelial-mesenchymal transition
- (2017) Guan-Sheng Shang et al. Oncology Letters
- Hypoxia-inducible factor-1 alpha Correlates with Tumor-Associated Macrophages Infiltration, Influences Survival of Gastric Cancer Patients
- (2017) Wei-jie Zhang et al. Journal of Cancer
- Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment
- (2017) Michael R. Cassidy et al. EBioMedicine
- Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy
- (2016) Laurent Dercle et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Warburg Effect: How Does it Benefit Cancer Cells?
- (2016) Maria V. Liberti et al. TRENDS IN BIOCHEMICAL SCIENCES
- Senescence of T Lymphocytes: Implications for Enhancing Human Immunity
- (2016) Arne N. Akbar et al. TRENDS IN IMMUNOLOGY
- Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study
- (2016) Christine A. Parkinson et al. PLOS MEDICINE
- Shifts in subsets of CD8+ T-cells as evidence of immunosenescence in patients with cancers affecting the lungs: an observational case-control study
- (2015) Oscar Okwudiri Onyema et al. BMC CANCER
- Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
- (2015) P F Ferrucci et al. BRITISH JOURNAL OF CANCER
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Biomarker: Predictive or Prognostic?
- (2015) Karla V. Ballman JOURNAL OF CLINICAL ONCOLOGY
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- (2015) Dung T. Le et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer
- (2015) PENGYUE SHI et al. Oncology Letters
- Increased expression of tumor necrosis factor-α is associated with advanced colorectal cancer stages
- (2015) Omar A Al Obeed WORLD JOURNAL OF GASTROENTEROLOGY
- Relationship between pretreatment levels of serum Cyfra 21.1, CEA and PET metabolic parameters in NSCLC
- (2014) Ismail Dogan et al. ANNALS OF NUCLEAR MEDICINE
- Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins
- (2014) M. F. Sanmamed et al. CLINICAL CANCER RESEARCH
- p38 signaling inhibits mTORC1-independent autophagy in senescent human CD8+ T cells
- (2014) Sian M. Henson et al. JOURNAL OF CLINICAL INVESTIGATION
- The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells
- (2014) Alessio Lanna et al. NATURE IMMUNOLOGY
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
- (2014) C. Bettegowda et al. Science Translational Medicine
- The Menin–Bach2 axis is critical for regulating CD4 T-cell senescence and cytokine homeostasis
- (2014) Makoto Kuwahara et al. Nature Communications
- Lung cancer circulating tumor cells isolated by the EpCAM-independent enrichment strategy correlate with Cytokeratin 19-derived CYFRA21-1 and pathological staging
- (2013) Qian Chen et al. CLINICA CHIMICA ACTA
- Cellular senescence and the senescent secretory phenotype: therapeutic opportunities
- (2013) Tamara Tchkonia et al. JOURNAL OF CLINICAL INVESTIGATION
- ANALYSIS OF CD8+CD28−T-SUPPRESSOR CELLS IN GASTRIC CANCER PATIENTS
- (2012) Yu Shen et al. JOURNAL OF IMMUNOASSAY & IMMUNOCHEMISTRY
- LDH-C4: a target with therapeutic potential for cancer and contraception
- (2012) G. S. Gupta MOLECULAR AND CELLULAR BIOCHEMISTRY
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Prognostic and Predictive Role of Lactate Dehydrogenase 5 Expression in Colorectal Cancer Patients Treated with PTK787/ZK 222584 (Vatalanib) Antiangiogenic Therapy
- (2011) M. I. Koukourakis et al. CLINICAL CANCER RESEARCH
- CD8+ CD28− and CD8+ CD57+ T cells and their role in health and disease
- (2011) Marius Strioga et al. IMMUNOLOGY
- Evaluation and Prognostic Significance of Circulating Tumor Cells in Patients With Non–Small-Cell Lung Cancer
- (2011) Matthew G. Krebs et al. JOURNAL OF CLINICAL ONCOLOGY
- Potential role of immunosenescence in cancer development
- (2010) Tamas Fulop et al. Annals of the New York Academy of Sciences
- Cytomegalovirus Infection Reduces Telomere Length of the Circulating T Cell Pool
- (2010) P. J. E. J. van de Berg et al. JOURNAL OF IMMUNOLOGY
- Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery
- (2010) S. Han et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Circulating Tumor Cell as a Diagnostic Marker in Primary Lung Cancer
- (2009) F. Tanaka et al. CLINICAL CANCER RESEARCH
- LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)
- (2009) Sanjiv S. Agarwala et al. EUROPEAN JOURNAL OF CANCER
- Baseline C-Reactive Protein Is Associated With Incident Cancer and Survival in Patients With Cancer
- (2009) Kristine H. Allin et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started